Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance
Author(s) -
Saeid Shahrabi,
Ali Akbar Ehsanpour,
Somayyeh Heidary,
Mohammad Shahjahani,
Masumeh Maleki Behzad
Publication year - 2018
Publication title -
oncology reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.637
H-Index - 21
eISSN - 1970-5565
pISSN - 1970-5557
DOI - 10.4081/oncol.2018.373
Subject(s) - medicine , myeloproliferative disorders , biomarker , clinical significance , abnormality , oncology , immunology , genetics , biology , psychiatry
Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders characterized by the presence of JAK2 mutation. Thrombohemorrhagic as well as autoimmune or inflammatory phenomena are common clinical outcomes of these disorders. Recent studies have shown that abnormality in frequency and function of blood cells manifested by an alteration in CD markers' expression patterns play a key role in these complications. So, there may be a relationship between CD markers' expressions and prognosis of JAK2 positive MPNs. Therefore, in this review, we have focused on these abnormalities from the perspective of changing expressions of CD markers and assessment of the relationship between these changes with prognosis of JAK2 positive MPNs. It can be stated that the abnormal expression of a large number of CD markers can be used as a prognostic biomarker for clinical outcomes including thrombohememorrhagic events, as well as autoimmune and leukemic transformation in JAK2 positive MPNs. Considering the possible role of CD markers' expressions in JAK2 MPNs prognosis, further studies are needed to confirm the relationship between the expression of CD markers with prognosis to be able to find an appropriate therapeutic approach via targeting CD markers.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom